ReviewFrontiers in immunology2022
Non-cytotoxic functions of CD8 T cells: "repentance of a serial killer".
Review in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 17 citations in OpenAlex.
- Menaquinone-4 protects CD8Science China. Life sciences · 2026Article
- Targeting Periodontitis with Treg-Derived Extracellular Vesicles: Modulation of Macrophages and CD8International journal of molecular sciences · 2026Article
- Stress-Related Immunomodulation of Canine Lymphocyte Responses and Hematologic Profiles.International journal of molecular sciences · 2026Article
- Metformin improves CD8+ T cell responses and parasitemia control via macrophage modulation during Trypanosoma cruzi infection.Journal of leukocyte biology · 2025Article
- cytoGPNet: Enhancing clinical outcome prediction accuracy using longitudinal cytometry data in small cohort studies.Patterns (New York, N.Y.) · 2025Article
- Bidirectional Communication Between the Innate and Adaptive Immune Systems.Annual review of immunology · 2025Review
- Chikungunya virus infection in the skin: histopathology and cutaneous immunological response.Frontiers in microbiology · 2025Article
- Tissue-resident memory T cells in urinary tract diseases.Frontiers in immunology · 2025Review
- Scm6A: A Fast and Low-cost Method for Quantifying m6A Modifications at the Single-cell Level.Genomics, proteomics & bioinformatics · 2024Article
- Recent Findings on Therapeutic Cancer Vaccines: An Updated Review.Biomolecules · 2024Review
- CTLs heterogeneity and plasticity: implications for cancer immunotherapy.Molecular cancer · 2024Review
- CD8 T cells are dispensable for experimental autoimmune prostatitis induction and chronic pelvic pain development.Frontiers in immunology · 2024Article
- Tumor growth suppression in adoptive T cell therapy via IFN-γ targeting of tumor vascular endothelial cells.Theranostics · 2024Article
- CD8+ Lymphocytes from Healthy Blood Donors Secrete Antiviral Levels of Interferon-Alpha.Viruses · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytotoxic CD8 T cells (CTLs) are classically described as the "serial killers" of the immune system, where they play a pivotal role in protective immunity against a wide spectrum of pathogens and tumors. Ironically, they are critical drivers of transplant rejection and autoimmune diseases, a scenario very similar to the famous novel "
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.